Clinical Significance of Late Gadolinium Enhancement on Cardiac Magnetic Resonance in Patients With Hypertrophic Cardiomyopathy

Carlos Dumont, a Lorenzo Monserrat, a Rafaela Soler, a Esther Rodríguez, a Xusto Fernández, a Jesús Peteiro, b Beatriz Bouzas, a Pablo Piñón, a and Alfonso Castro-Beiras a

aServicio de Cardiología, Juan Canalejo Hospital, A Coruña, Spain
bServicio de Radiología, Juan Canalejo Hospital, A Coruña, Spain

Introduction and objectives. In patients with hypertrophic cardiomyopathy, myocardial fibrosis can be detected by late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging. We investigated the relationships between the extent of LGE, left ventricular morphology and function, and clinical characteristics.

Methods. Both cine and gadolinium-enhanced magnetic resonance imaging were performed in 104 patients with hypertrophic cardiomyopathy.

Results. Fifty patients (48%) showed LGE (range: 1–11 segments). The extent of LGE was positively correlated with maximum left ventricular wall thickness (r=0.53; P<0.001), left ventricular mass (r=0.41; P<0.001), and the number of hypokinetic segments (r=0.51; P<0.001), and inversely correlated with ejection fraction (r=−0.32; P<0.001). The magnitude of the subaortic gradient increase during exercise echocardiography (r=−0.26; P=0.023), and age at diagnosis (r=−0.20; P=0.04). Four of the 5 patients with an ischemic response on exercise echocardiography had LGE (range: 1–11 segments). The extent of LGE was positively correlated with the number of LGE segments increased more frequently as the number of LGE segments increased (P<0.001 and P=0.04, respectively).

Conclusions. Extensive LGE reflects greater disease expression. It is associated with more severe myocardial damage (e.g., a lower ejection fraction and a larger number of hypokinetic segments) and with adverse clinical characteristics (e.g., young age at diagnosis, severe hypertrophy, nonsustained ventricular tachycardia, and an ischemic response on exercise), suggesting that it may be closely linked to prognosis.

Key words: Hypertrophic cardiomyopathy. Magnetic resonance imaging. Prognosis.

Introducción y objetivos. La fibrosis miocárdica puede ser detectada en la miocardiopatía hipertrófica (MCH) mediante resonancia magnética cardíaca (RM) con realce tardío de gadolinio (RT). Analizamos la relación entre la extensión del RT y la morfología y función del ventrículo izquierdo (VI) y los datos clínicos.

Métodos. Estudiamos con RM a 104 pacientes diagnosticados de MCH. Se obtuvieron secuencias de cine-RM y secuencias de realce tardío.

Resultados. Cincuenta pacientes presentaron RT (48%; rango: 1-11 segmentos). La extensión del RT se correlacionó positivamente con el grosor máximo (r = 0.53; p < 0.001), la masa (r = 0.41; p < 0.001) y el número de segmentos hipocinéticos (r = 0.51; p < 0.001) del ventrículo izquierdo, e inversamente con la fracción de eyeción (r = −0.26; p = 0.001), la capacidad de incrementar el gradiente subaórtico durante la ecocardiografía de ejercicio (r = −0.20; p = 0.04). Cuatro de los 5 pacientes con una respuesta isquémica en la ecocardiografía de ejercicio presentaron ≥3 segmentos con RT (p = 0.001). La hipertrofia severa (≥30 mm) y la taquicardia ventricular no sostenida (TVNS) se asociaron con la extensión del RT (p < 0.001 y p = 0.04, respectivamente).

Conclusiones. La extensión del RT refleja una mayor expresión de esta enfermedad. Se asocia con un mayor riesgo de muerte súbita y progresión a un cuadro de enfermedad cardíaca más severo (menor fracción de eyeción y mayor número de segmentos hipocinéticos) y con parámetros clínicos adversos (edad más joven en el momento del diagnóstico, hipertrofia severa, TVNS y respuesta isquémica al ejercicio), lo que indica que podría vincularse al pronóstico.

Palabras clave: Miocardiopatía hipertrófica. Resonancia magnética. Pronóstico.

INTRODUCTION

Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disease with variable penetrance and heterogeneous clinical expression. Although several risk factors have been shown to be associated with increased risk for sudden death and progression to a dilated phase, the predictive accuracy of each of these
Late Enhancement on Hypertrophic Cardiomyopathy

Factors for Sudden Death in a Large Cohort of Patients with HCM.

For risk stratification and evolution of symptoms, thus the time between the CMR scan, and the other procedures was, in general, no longer than a year.

Five clinical risk factors for sudden death were used to stratify patients: family history of sudden premature cardiac death; unexplained syncope; non-sustained ventricular tachycardia (one or more runs of ≥3 consecutive ventricular extrasystoles at ≥120 beats/min, lasting for less than 30 seconds); an abnormal blood pressure response during upright exercise testing in subjects ≤40 years old (failure of systolic blood pressure to rise by more than 25 mmHg from baseline values or a fall of more than 10 mmHg from the maximum blood pressure during upright exercise); and presence of severe left ventricular hypertrophy (wall thickness ≥50mm).

In an attempt to ascertain the clinical significance of LGE in HCM, we analyzed the relationship between the extent of LGE and left ventricular (LV) morphology and function, symptoms, functional capacity, and clinical risk factors for sudden death in a large cohort of patients with HCM.

METHODS

Patient Population

Over a 26-month period, cardiac magnetic resonance (CMR) studies were performed in 104 consecutive patients from our cohort of 360. We systematically ask for CMR studies in our patients with HCM, excluding patients with implantable cardioverter-defibrillators (ICDs), pacemakers, and atrial fibrillation because of difficulties in performing CMR. We also excluded for this study patients who underwent myectomy, alcohol septal ablation, or valve replacement prior to CMR and patients with known, or suspected coronary artery disease. HCM was diagnosed by the presence of a non-dilated and hypertrophied left ventricle (maximal wall thickness ≥15 mm in adult patients or ≥13 mm in adult relatives of a HCM patient) in the absence of another cardiac or systemic disease (eg, hypertension or aortic stenosis) capable of producing the magnitude of hypertrophy observed.11,12,13

Clinical Evaluation

Clinical evaluation included history, physical examination, 12 lead ECG, echocardiography, 24h ECG monitoring analysis, and conventional exercise testing, or exercise echocardiography with assessment of blood pressure, and ischemic response. HCM patients undergo comprehensive clinical assessments on an annual basis for risk stratification and evolution of symptoms, thus the time between the CMR scan, and the other procedures was, in general, no longer than a year.

Five clinical risk factors for sudden death were used to stratify patients: family history of sudden premature cardiac death; unexplained syncope; non-sustained ventricular tachycardia (one or more runs of ≥3 consecutive ventricular extrasystoles at ≥120 beats/min, lasting for less than 30 seconds); an abnormal blood pressure response during upright exercise testing in subjects ≤40 years old (failure of systolic blood pressure to rise by more than 25 mmHg from baseline values or a fall of more than 10 mmHg from the maximum blood pressure during upright exercise); and presence of severe left ventricular hypertrophy (wall thickness ≥50mm).

Of the 104 patients studied with CMR, all had two-dimensional and Doppler echocardiogram, 96 (92%) had 24h ECG monitoring analysis and 93 (90%) were assessed for an abnormal blood pressure response on exercise, 73 patients with exercise echocardiography and 20 patients with conventional exercise testing.

Cardiac Magnetic Resonance

Image Acquisition

All CMR images were obtained with a 1.5-T system (Gyroscan NT; Philips Medical Systems, Best, The Netherlands) in conjunction with a phased-array body coil and electrocardiogram gating.

Scout images were obtained in 3 orthogonal planes to determine the exact position and axis of the left ventricle. Cine-MR images of the left ventricle were obtained using a turbo gradient recalled echo sequence (repetition time ms/echo time ms, 11/4; field of view (FOV), 400 mm; matrix, 147×11; flip angle, 20°). The cine-MR sequences were obtained during expiration in the following planes: a short-axis view of the left ventricle from base to apex with eight to ten sections, one horizontal long axis view of the left ventricle, and one vertical long axis view in two left atrium-left ventricle chambers.

Myocardial tissue tagging gradient-echo echo-planar sequence (repetition time/echo time/echo-planar factor, 750/16/13 ms; flip angle, 13°; FOV, 400 mm; matrix, 102×256; slice thickness, 10 mm; orthogonal grid, 10 mm) was run during expiratory breath-hold and three short-axis planes (basal, midventricular, and apical) were obtained.

Delayed contrast-enhanced images were acquired 10 minutes after the injection of the contrast material according to a previous report,14 with an inversion
recovery T1-weighted sequence (repetition time/echo time ms, 8/4.5, flip angle 15º. FOV, 400 mm; matrix, 144x256; and section thickness, 10 mm) in 3 short-axis views taken at the base, midpapillary muscles, and the apex; 1 horizontal long-axis view; and 1 vertical long-axis view. The time of inversion was adjusted for each patient between 200 and 400 ms to achieve optimal suppression of normal myocardium.15,16 The CMR studies were completed on all patients without complications.

Image Analysis

All CMR images were analyzed on a satellite workstation console with commercial image post-processing software (EasyVision, version 4.0; Philips Medical Systems) by 2 radiologists with experience in cardiac MR imaging (RS and ER), whose joint opinion was reached by consensus. The CMR studies were read blinded to the clinical information.

The American Heart Association 17-segment model for the left ventricle17 was used to analyze wall thickness, contractile function, and delayed enhancement per segment. Three representative short-axis slices obtained at the base, mid-ventricle, and apex were divided into 6, 6, and 4 segments, respectively. The true apex (segment 17) was analyzed on the horizontal or vertical long axis of the left ventricle.

Endocardial and epicardial contours were traced manually at end-diastole and end-systole on the short-axis cine sets in order to measure left ventricular volumes, and calculate the LV mass, stroke volume, the ejection fraction, and the cardiac output.

Wall motion at rest was visually assessed as a change in myocardial tagging grip shape with respect to the original diastolic pattern. Circumferential segment shortening was judged as normal, hypokinetic, or dyskinetic in each myocardial segment.

Late gadolinium enhancement was considered present in 12 patients (11%), non-sustained ventricular tachycardia in 19 (18%), and abnormal blood pressure response on exercise test in 31 (30%). Forty-four patients (42%) had no risk factor for sudden death (42%), 19 (18%) reported exertional chest pain, and high blood pressure >240 mm Hg or diastolic blood pressure >110 mm Hg, severe hypertensive response (decrease >20 mm Hg from baseline), or limiting symptoms were present. The development of a new regional dysfunction or worsening from a previous hypokinetic region to akinesia was considered an ischemic response, as well as the decrease of LV ejection fraction >5% at the end of exercise.24,25 Differences of ejection fraction and subaortic gradient between basal, and peak exercise conditions were correlated with the number of segments with LGE. Exercise echocardiography assessment was performed by one investigator (J.P.), who was blinded to the clinical data.

Statistical Analysis

Data were analyzed using the SPSS software (version 12.0). Patients were classified in four groups on the basis of number of segments with late-enhancement: 0, 1, 2, or ≥3. The χ² for trend was used to test for an association between these groups and each dichotomous baseline variable. Continuous variables were expressed as mean (SD) and associations were tested by linear regression. A P value less than .05 was considered significant.

RESULTS

Population Characteristics

There were 67 (65%) males and 37 (35%) women. Mean age at diagnosis was 43 years (12 - 76) and at the time of CMR imaging was 51 years (16 - 78). Most patients (98%) were in NYHA functional class I (50%) or II (48%); 19 (18%) reported exertional chest pain; and 4 (8%) previous syncope. Maximal left ventricular wall thickness on echo was ≥21 (6) mm (≥30 mm in 13 patients) and there was a subaortic gradient ≥30 mm Hg in 36 patients (55%). Family history of sudden death was present in 12 patients (11%), non-sustained ventricular tachycardia in 19 (18%), and abnormal blood pressure response on exercise test in 31 (30%). Forty-four patients had no risk factor for sudden death (42%), 42 (41%) had one, 14 (13%) had two, 3 (3%) had three, and 1 patient (1%) had four risk factors. Medical treatment used during follow-up included beta-blockers (65% of the patients), calcium antagonists (28%), disopyramide (3%), amiodarone (19%), acenocumarol (12%), ACE inhibitors (13%), and small doses of diuretics (20%). During the follow-up, 8 patients received an ICD (clinical data in Table 1), 4 alcohol septal ablation, and 1 patient underwent septal myectomy.
Patient ranged from 1 to 15 (mean: 6 [3]). Asymmetrical hypertrophy was present in 67 patients (65%), symmetrical in 25 (24%), and apical in 12 (11%). Hypertrophy was observed most frequently in anterior and posterior portions of the upper and middle septum.

Late enhancement was observed in 50 patients (48%), or in 131 segments (8%) out of 1768 segments, ranging from 1 to 11 segments per patient. Late enhancement occurred most frequently within hypertrophied regions of the interventricular septum. The delayed enhancement patterns observed were: diffuse or confluent patchy mural foci (70%), subendocardial (10%), small foci (14%) and subepicardial (6%) (Figure 1).

**TABLE 1. Clinical, Echocardiographic and CMR Data on 4 Patients Who Received ICD**

<table>
<thead>
<tr>
<th></th>
<th>Secondary</th>
<th>Primary</th>
<th>Primary</th>
<th>Primary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary or secondary prevention</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Age (years)</td>
<td>32</td>
<td>48</td>
<td>36</td>
<td>22</td>
</tr>
<tr>
<td>Gender</td>
<td>M</td>
<td>F</td>
<td>F</td>
<td>F</td>
</tr>
<tr>
<td>NYHA Class</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
</tr>
<tr>
<td>Symptoms</td>
<td>None</td>
<td>Chest pain</td>
<td>Chest pain</td>
<td>None</td>
</tr>
<tr>
<td>Medication</td>
<td>Beta-blocker</td>
<td>Beta-blocker</td>
<td>Beta-blocker</td>
<td>Beta-blocker</td>
</tr>
<tr>
<td>Family history of sudden death</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Syncope</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Abnormal BP response to exercise</td>
<td>no</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Maximal LV wall thickness, mm</td>
<td>35</td>
<td>19</td>
<td>20</td>
<td>32</td>
</tr>
<tr>
<td>LV outflow gradient, mm Hg</td>
<td>100</td>
<td>13</td>
<td>10</td>
<td>30</td>
</tr>
<tr>
<td>Presence of late-enhancement</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Number of late-enhancement segments</td>
<td>3</td>
<td>4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>LV ejection fraction, %</td>
<td>65</td>
<td>65</td>
<td>55</td>
<td>70</td>
</tr>
<tr>
<td>LV mass, g</td>
<td>414</td>
<td>141</td>
<td>250</td>
<td>260</td>
</tr>
</tbody>
</table>

*NYHA indicates New York Heart Association functional class; BP, blood pressure; VT, ventricular tachycardia.

**Figure 1.** A 44 year-old man with non-obstructive hypertrophic cardiomyopathy, two risk factors for sudden death (non-sustained ventricular tachycardia and maximum wall thickness of 35 mm), LV ejection fraction of 65%, LV mass of 400 g, and 5 segments with late enhancement and hypokinesia at interventricular septum. A: horizontal long axis. B: short axis views on contrast-enhanced CMR images demonstrate confluent mural high signal intensity at the entire thickened septum.
of the hypokinetic segments presented LGE, of the 111 segments only 75 had LGE.

**Extent of Late Enhancement Related to Clinical Data**

Table 2 summarizes the relation of LGE with age, symptoms, exercise test parameters, and risk factors for sudden death. There was no relationship between the extent of LGE and patients age at the time of CMR imaging ($P=0.3$), but the number of LGE segments was inversely correlated with age at diagnosis ($r=-0.20; P=0.04$). With regard to sudden death risk factors profile, there was a higher proportion of wall thickness $\geq 30$ mm and non-sustained ventricular tachycardia (NSVT) with increasing the number of LGE segments ($P<0.01$ and $P=0.04$, respectively). There were no significant differences in therapy and risk factors for coronary artery disease among LGE groups.

Two patients presented an ejection fraction $<50\%$ with a non-dilated LV, one with 2, and the other with 3 segments with LGE. The increase in subaortic gradient during exercise echocardiography correlated inversely with the number of LGE segments ($r=-0.26; P=0.023$). An ischemic response on exercise echocardiography was reported in 5 patients, and four of them had $\geq 3$ segments with LGE ($P=0.003$). Of the 5 patients with an ischemic response, 3 had angiographically normal coronary arteries and the other two patients did not have angina, or other symptoms indicative of coronary artery disease, and were reluctant to undergo a coronary angiography (one with a sepal diffuse patchy LGE pattern and the other with a subepicardial pattern).

Table 3 shows the relation between LGE and other CMR parameters. The extent of LGE correlated positively with the LV maximum wall thickness ($r=0.53; P<0.001$), the LV mass ($r=0.41; P<0.001$) and the number of hypokinetic segments ($r=0.51; P<0.001$), and inversely with the ejection fraction ($r=-0.32; P=0.001$) (Figure 2).

**DISCUSSION**

Myocardial fibrosis plays an important part in both sudden cardiac death and end stage disease as shown by

---

**TABLE 2. Relation of Late Gadolinium Enhancement With Symptoms, Exercise Parameters, and Risk Factors for Sudden Death**

<table>
<thead>
<tr>
<th>Number of Segments With Late-Enhancement</th>
<th>0 (n=54)</th>
<th>1 (n=19)</th>
<th>2 (n=12)</th>
<th>$\geq 3$ (n=19)</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demography</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, y</td>
<td>51 (16-78)</td>
<td>54 (31-72)</td>
<td>52 (21-76)</td>
<td>47 (22-74)</td>
<td>.3†</td>
</tr>
<tr>
<td>Age at diagnosis, y</td>
<td>46 (13)</td>
<td>41 (14)</td>
<td>44 (17)</td>
<td>37 (15)</td>
<td>.04‡</td>
</tr>
<tr>
<td>Male sex</td>
<td>39 (72%)</td>
<td>11 (58%)</td>
<td>8 (67%)</td>
<td>9 (47%)</td>
<td>.07†</td>
</tr>
<tr>
<td><strong>Clinical</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NYHA II</td>
<td>26 (48%)</td>
<td>7 (37%)</td>
<td>6 (50%)</td>
<td>11 (58%)</td>
<td></td>
</tr>
<tr>
<td>NYHA III/IV</td>
<td>1 (2%)</td>
<td>0</td>
<td>0</td>
<td>1 (5%)</td>
<td>.3†</td>
</tr>
<tr>
<td>NYHA III/IV episodes</td>
<td>8 (15%)</td>
<td>1 (5%)</td>
<td>1 (8%)</td>
<td>4 (21%)</td>
<td>.7†</td>
</tr>
<tr>
<td>NYHA III/IV episodes</td>
<td>7 (13%)</td>
<td>4 (21%)</td>
<td>2 (16%)</td>
<td>0</td>
<td>.2†</td>
</tr>
<tr>
<td>Atrial fibrillation episodes</td>
<td>7 (14%)</td>
<td>3 (17%)</td>
<td>2 (20%)</td>
<td>7 (37%)</td>
<td>.04‡</td>
</tr>
<tr>
<td>Family history sudden death</td>
<td>5 (9%)</td>
<td>1 (5%)</td>
<td>3 (25%)</td>
<td>3 (16%)</td>
<td>.2†</td>
</tr>
<tr>
<td>Non-sustained VT</td>
<td>7 (14%)</td>
<td>3 (17%)</td>
<td>2 (20%)</td>
<td>7 (37%)</td>
<td>.04‡</td>
</tr>
<tr>
<td>Abnormal BP response</td>
<td>19 (40%)</td>
<td>4 (25%)</td>
<td>4 (40%)</td>
<td>4 (25%)</td>
<td>.2†</td>
</tr>
<tr>
<td>Syncope</td>
<td>6 (11%)</td>
<td>0</td>
<td>1 (8%)</td>
<td>1 (5%)</td>
<td>.4‡</td>
</tr>
<tr>
<td>Subaortic gradient $\geq 30$ mm Hg</td>
<td>19 (35%)</td>
<td>6 (31%)</td>
<td>5 (42%)</td>
<td>6 (32%)</td>
<td>.9‡</td>
</tr>
<tr>
<td>Wall thickness $\geq 30$ mm</td>
<td>1 (2%)</td>
<td>2 (10%)</td>
<td>3 (25%)</td>
<td>7 (37%)</td>
<td>&lt;0.01‡</td>
</tr>
<tr>
<td><strong>Exercise echocardiography</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>METS</td>
<td>10 (3)</td>
<td>11 (2)</td>
<td>9 (3)</td>
<td>10 (3)</td>
<td>.3‡</td>
</tr>
<tr>
<td>Ischemic response</td>
<td>0</td>
<td>1 (9%)</td>
<td>0</td>
<td>4 (25%)</td>
<td>.003‡</td>
</tr>
<tr>
<td>Gradient difference $\geq 30$ mm Hg</td>
<td>41 (1-250)</td>
<td>18 (1-100)</td>
<td>1 (20-28)</td>
<td>15 (2-68)</td>
<td>.023‡</td>
</tr>
<tr>
<td>Risk factors for sudden death</td>
<td>8 (15%)</td>
<td>1 (5%)</td>
<td>3 (25%)</td>
<td>6 (32%)</td>
<td>.09‡</td>
</tr>
</tbody>
</table>

*Data are presented as the mean value (SD) or range, or number (%) of subjects. NYHA indicates New York Association functional class; VT, ventricular tachycardia; BP, blood pressure; gradient difference, post-exercise-basal gradient.

$†\chi^2$ for trend.

‡Linear regression (the number of segments with LGE was considered as a continuous variable).
necropsy studies, but its role in developing disease has not been established because of the lack of an in vivo quantification technique. Late gadolinium enhancement CMR provides a means of quantifying fibrosis in vivo in HCM and gives a new tool in order to better characterize the phenotype of this disease. This study, with the largest sample size of HCM studied with CMR to date, supports the clinical perspective that myocardial fibrosis, detected as LGE, may play an important role in disease expression.

LGE Related to Risk Factors for Sudden Death

Identifying patients at higher risk is an important aspect of the clinical management of HCM, particularly considering that effective preventive therapy is available (ICDs). The need for accurate risk stratification is challenging, taking into account that HCM patients who undergo ICD implantation are younger than patients with coronary artery disease and it is likely that their lifetime risk of serious ICD related complications will be high. LGE may potentially identify a substrate for increased risk for sudden death. The fact that most patients with severe hypertrophy or NSVT did not die suddenly and that many sudden deaths occur in patients with a maximum wall thickness less than 30 mm or without NSVT, reflects the need for more accurate risk stratification and in these terms the extent of LGE may play a role. However, it is important to highlight that although the extent of LGE may relate to malignant ventricular arrhythmias, the presence of LGE in itself should not be considered as indicative of an adverse prognosis, since LGE is a common finding in HCM (50% in our study) and the overall risk of sudden death in our patient population is low (<1%). Moreover, the absence of LGE probably will not have a high negative predictive value. For example, one patient who received an ICD for primary prevention, presented multiple prolonged runs of NSVT and did not show LGE (Table 1). This may be explained by the fact that image contrast of LGE is created by suppressing normal myocardium and diffuse myocardial involvement can potentially be missed.

On the other hand, the expression of this abnormal substrate is, in turn, influenced by factors such as autonomic tone and myocardial ischemia. In our study, an ischemic response during exercise echocardiography was not commonly observed, contrary to a previous dobutamine exercise echocardiography study, but its presence was linked to greater extent of LGE, which reflects another adverse clinical marker in this group of patients.

TABLE 3. Late Enhancement and Other CMR Parameters*

<table>
<thead>
<tr>
<th>Number of Segments With Late-Enhancement</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 (n=54)</td>
<td>13 (3)</td>
<td>14 (3)</td>
<td>16 (4)</td>
<td>15 (3)</td>
<td>.001†</td>
</tr>
<tr>
<td>Maximum wall thickness</td>
<td>20 (14-32)</td>
<td>23 (16-36)</td>
<td>29 (16-42)</td>
<td>28 (18-41)</td>
<td>&lt;.001†</td>
</tr>
<tr>
<td>Number of hypertrophied segments</td>
<td>4 (1-11)</td>
<td>6 (1-14)</td>
<td>7 (2-15)</td>
<td>8 (3-15)</td>
<td>&lt;.001†</td>
</tr>
<tr>
<td>LV mass, g</td>
<td>171 (67)</td>
<td>200 (75)</td>
<td>237 (74)</td>
<td>252 (91)</td>
<td>&lt;.001†</td>
</tr>
<tr>
<td>LA H, mm</td>
<td>45 (9)</td>
<td>44 (9)</td>
<td>44 (9)</td>
<td>46 (6)</td>
<td>.6†</td>
</tr>
<tr>
<td>LVES volume, mL</td>
<td>92 (26)</td>
<td>96 (26)</td>
<td>90 (28)</td>
<td>96 (26)</td>
<td>.6†</td>
</tr>
<tr>
<td>LVED volume, mL</td>
<td>21 (8)</td>
<td>22 (7)</td>
<td>28 (12)</td>
<td>33 (19)</td>
<td>&lt;.001†</td>
</tr>
<tr>
<td>Ejection fraction, %</td>
<td>76 (7)</td>
<td>74 (8)</td>
<td>70 (9)</td>
<td>69 (10)</td>
<td>.001†</td>
</tr>
</tbody>
</table>

Pattern of hypertrophy

Asymmetric septal hypertrophy 32 (59%) 12 (63%) 8 (67%) 5 (79%) 15 (79%)
Symmetric 20 (37%) 1 (5%) 1 (8%) 3 (16%) 3 (16%)
Apical 2 (4%) 6 (39%) 3 (25%) 1 (5%) 1 (5%)
Presence of hypokinesia 5 (9%) 5 (26%) 5 (41%) 12 (63%) <.001†
No. segments with hypokinesia 0.25 (0.5) 1 (0.5) 1.75 (0.6) 3 (0.8) <.001†

*Data are presented as the mean value (SD) or range, or number (%) of subjects. LVED indicates left-ventricular end-diastolic; LVES, left-ventricular end-systolic; LA, left atrium diameter in horizontal long axis view.
†χ² for trend.
‡Linear regression (the number of segments with LGE was considered as a contiguous variable).
Although we did not find any association between the extent of LGE and patient age at the time of CMR scan, LGE extent was associated with an earlier diagnosis of the disease. This may imply that in some patients, extensive myocardial fibrosis does not need time to develop and large amount of fibrosis could be present at a young age. Moreover, the rate of LGE development may be important and extensive LGE at a young age may carry more significance than a similar degree of LGE in an older patient.

LGE Related to Systolic Dysfunction

Previous studies showed that LGE extent is associated with lower ejection fraction and with progressive ventricular dilation.\textsuperscript{16,17} Additional evidence that suggests a relation between the extent of LGE and systolic impairment is our finding of a positive correlation with the number of segments with hypokinesia and inverse correlations with the LV ejection fraction, and the capacity to increase subaortic gradient during exercise. The clinical course of end-stage phase in HCM proved to be variable, unpredictable, and generally unfavourable.\textsuperscript{34,35} Clinical markers that reliably anticipate evolution to systolic dysfunction are difficult to define in an heterogeneous disease like this. However, the extent of LGE with the other clinical features (young age at diagnosis, greater wall thickness, etc)\textsuperscript{34,35} may help us identify a subgroup of patients in which a close follow up may be warranted.

CONCLUSIONS

Late gadolinium enhancement has a great potential to provide new insights in the assessment of patients with HCM. The extent of LGE reflects a greater expression of this disease. It is associated with a more severe myocardial damage (lower ejection fraction and increased number of hypokinetic segments) and adverse clinical parameters (younger age at diagnosis, non-sustained ventricular tachycardia, severe hypertrophy, and ischemic response on exercise echocardiogram), suggesting it may be linked to prognosis. A follow up of this population will help us to evaluate the predictive accuracy of this technique for both sudden cardiac death and the development of systolic dysfunction.

Study Limitations

First, we estimated the extent of late enhancement in a semiquantitative way compared with the measurement of the volume of hyperenhrancing lesions evaluated in previous studies.\textsuperscript{16,17} This methodological approach could...
explain the difference between our study and previous with regard to the strength of relationships observed between the extent of LGE and markers of clinical risk. However, this difference and the lower incidence of LGE in our study compared with previous may also be explained by different enroling criteria and sample size. Choudhury et al studied only 21 HCM patients and Moon et al chose patients with high or low clinical risk factors for sudden death rather than taking a population “consecutively enrolled” as here. Our study confirms that the quantification of the extent of late gadolinium enhancement using the standardized myocardial segmentation model for tomographic imaging of the heart is clinically relevant and easily available for clinical application.

Second, although all patients with documented coronary artery disease were excluded from this study, only patients with typical chest pain or symptoms indicative of coronary disease underwent coronary angiography, being possible that some patients with coronary artery disease were included. However, none of the patients with an ischaemic response on exercise echocardiography had a LGE pattern indicative of coronary artery disease.

REFERENCES
